Company / SG&A Expense
Trevi Therapeutics, Inc. SG&A Expense History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.1M
FY2024
5-year range
$9.5M / $12.1M
FY2020-FY2024
Trend
+18.6%
vs FY2023
Sector context
#208 of 213
Health Care
What the data says
Among 213 Health Care companies, Trevi Therapeutics, Inc. is in the top 2% for sg&a expense. SG&A Expense has increased for 3 consecutive years, from $9M in FY2021 to $12M in FY2024.
Based on SEC 10-K filings.
$12M in FY2024 with a 5-year CAGR of +10.7%.
Increased from $10M to $12M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +10.7%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 213This company $12.1M Sector average $722.3M
▼
-98.3% below sector average
Key checks
Key Insights
- Trevi Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +10.7%, indicating consistent growth.
- In FY2024, sg&a expense increased 18.6% year-over-year.
- Ranks #208 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.1M | +18.6% |
| FY2023 | $10.2M | +1.7% |
| FY2022 | $10.1M | +6.1% |
| FY2021 | $9.5M | -6.6% |
| FY2020 | $10.2M | +39.1% |
| FY2019 | $7.3M | +68.5% |
| FY2018 | $4.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026